RCEL
NASDAQAvita Medical
$7.77
+3.02 (+63.58%)
2026-08-07 00:00
Healthcare
Medical Devices
--
--
Short Interest (1 Year)
% of Volume Sold ShortMarket Cap
$146.2M
P/E Ratio
N/A
52W Low
52W High
$3.22
$8.07
Volume
7.2M
Analyst Rating
Hold
Target: $8
10 Analyst Ratings
Strong Buy
0
Buy
0
Hold
10
Sell
0
Price Target Range
Low: $7
Avg: $8
High: $9
About Avita Medical
AVITA Medical, Inc., together with its subsidiaries, operates as a therapeutic acute wound care company in the United States, Japan, the European Union, Australia, and the United Kingdom. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds and full-thickness skin defects, as well as for repigmentation of stable depigmented vitiligo lesions. It also provides RECALL autologous cell harvesting device, which can treat areas of up to...
Employees
226
Website
avitamedical.com
Financial Highlights
Annual
Quarterly
| Year | Revenue | Op Margin | Net Income | Free Cash Flow |
|---|---|---|---|---|
| 2025 | $71.6M | -59.4% | -$48.6M | -$29.5M |
| 2024 | $64.3M | -88.1% | -$61.8M | -$39.6M |
| 2023 | $50.1M | -85.1% | -$35.4M | -$36.6M |
| 2022 | $34.4M | -79.9% | -$26.7M | -$18.6M |
| 2022 | N/A | N/A% | N/A | -$17.6M |
| 2026 Q1 | $19.3M | -45.7% | -$10.6M | -$10.1M |
| 2025 Q4 | $17.6M | -59.1% | -$11.6M | -$3.7M |
| 2025 Q3 | $17.1M | -53.6% | -$13.2M | -$4.3M |
| 2025 Q2 | $18.4M | -60.5% | -$9.9M | -$9.7M |
| 2025 Q1 | $18.5M | -63.9% | -$13.9M | -$10.1M |
| 2024 Q4 | $18.4M | -54.1% | -$11.6M | -$6.4M |
| 2024 Q3 | $19.5M | -70.6% | -$16.2M | -$3.4M |
| 2024 Q2 | $15.2M | -102.8% | -$15.4M | -$10.1M |